Review ArticlesIcotinib efficacy in different solid tumors and gene mutationsZhao, Qiana,,*; Cheng, Jiea,,*; Chen, Pingpingb; Sun, Jieweia; Guan, ShengjiangaAuthor Information aDepartment of Pharmacy, Hebei Hospital of Chinese Medicine bSchool of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China * Qian Zhao and Jie Cheng are joint first authors. Received 5 July 2019 Revised form accepted 13 October 2019 Correspondence to Shengjiang Guan, MD, Hebei Hospital of Chinese Medicine, Shijiazhuang 050200, Hebei, China, Tel: +86 0311 69095114; fax: +86 0311 69095004; e-mail: firstname.lastname@example.org Anti-Cancer Drugs: March 2020 - Volume 31 - Issue 3 - p 205-210 doi: 10.1097/CAD.0000000000000861 Buy Metrics Abstract Icotinib is a first-generation inhibitor of epidermal growth factor receptor, which has been approved by the Chinese National Medical Products Administration, for the treatment of non-small cell lung cancer with epidermal growth factor receptor sensitive mutations. In addition, icotinib also shows moderate activity in other solid tumors driven by epidermal growth factor receptor, including non-small cell lung cancer with epidermal growth factor receptor rare non-resistant mutations, and esophageal cancer with epidermal growth factor receptor amplification or overexpression. This article reviews the efficacy of icotinib in different solid tumors with different epidermal growth factor receptor alterations. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.